Sector News

Levi Garraway, M.D., Ph.D., to become SVP of Global Oncology at Lilly

September 14, 2016
Life sciences

Eli Lilly and Company today announced that Levi Garraway, M.D., Ph.D., a world leader in the analysis of cancer genomics and resistance to targeted therapies, will join Lilly as senior vice president, Global Development & Medical Affairs, for Lilly’s Oncology business on January 1, 2017.

Dr. Garraway will succeed Richard Gaynor, M.D., who will retire after a distinguished career at Lilly.

Dr. Garraway is currently associate professor of medicine in the Department of Medical Oncology at the Dana-Farber Cancer Institute and Harvard Medical School, an associate physician at the Brigham and Women’s Hospital, an Institute Member of the Broad Institute of MIT and Harvard, and an investigator of the Howard Hughes Medical Institute. He will report to Sue Mahony, Ph.D., Lilly senior vice president and president of Lilly Oncology. “We are pleased and honored to have Dr. Garraway join us at Lilly,” Mahony said. “He has made a tremendous impact in his career and is recognized around the world as a leader in oncology.

“We know he will provide keen insight and expertise—and will continue to advance Lilly’s work in developing innovative new medicines to truly make life better for people with cancer around the world.”

Mahony praised Dr. Gaynor for his significant contributions to the discovery and development of cancer medicines. “Richard is known for scientific rigor and deep expertise in drug development, coupled with a personal warmth and care for patients that is truly inspiring,” she said. “He is leaving a remarkable legacy at Lilly through his impact on the pipeline, people and patients.”

About Levi Garraway, M.D., Ph.D.
A graduate of Harvard Medical School, Garraway is director of the Joint Center for Cancer Precision Medicine, which spans Harvard teaching hospitals: Dana-Farber Cancer Institute, Brigham and Women’s Hospital, Boston Children’s Hospital, and the Broad Institute of MIT and Harvard. He is also co-leader of the Cancer Genetics Program at the Dana-Farber/Harvard Cancer Center.

In addition to his work at Harvard, Dr. Garraway is on the boards of major cancer centers, including Sloan Kettering, MD Anderson and Ohio State, and he is chairman of several major National Institutes of Health (NIH) committees. He also serves on the American Association for Cancer Research (AACR) board of directors and was elected president of the American Society of Clinical Investigation–one of the highest honors for academic clinician scientists.

He is the author of nearly 200 peer-reviewed scientific articles and has received many awards, including the Paul Marks Prize for Cancer Research, the Jane Cooke Wright Award from AACR, the New Innovator Award from the NIH, and an Outstanding Investigator Award from the National Cancer Institute.

Dr. Garraway’s industry activities also include being a founder of Foundation Medicine, a leading company in cancer genomics diagnostics.

Source: Eli Lilly and Company

comments closed

Related News

May 15, 2022

Novo Nordisk and Flagship Pioneering announce a strategic collaboration to create a portfolio of transformational medicines

Life sciences

The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.

May 15, 2022

BD, Babson set sights on bringing simple blood collection into the home

Life sciences

BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.

May 15, 2022

CSL’s $11.7B Vifor buy, 2021’s biggest biopharma M&A deal, hits antitrust delay

Life sciences

Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.